Navigation Links
Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat

WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced the results of a new study indicating that HIV resistant to Protease Inhibitors (PI) may have reduced potential for the development of resistance to the HIV maturation inhibitor bevirimat in laboratory assays. The study, carried out by scientists in Dr. Eric Freed's group at the HIV Drug Resistance Program at the National Cancer Institute, Frederick, MD, in collaboration with Panacos, was presented at the Cold Spring Harbor Laboratory's (CSHL) Retrovirus Conference held May 22-27, 2007 in Cold Spring Harbor, NY.

While resistance to bevirimat has not yet been reported in clinical studies, bevirimat-resistant HIV can be generated in the laboratory, as is the case with other HIV drugs. In previous studies where HIV was grown for several weeks in cell culture in the presence of bevirimat at suboptimal concentrations, mutations conferring resistance to bevirimat were found exclusively at or near bevirimat's target, the capsid-SP1 cleavage site in the HIV Gag protein. Cleavage of capsid from SP1, the final step in viral maturation, is mediated by the viral protease enzyme. Bevirimat inhibits this cleavage step by interacting with the capsid-SP1 junction in Gag, suggesting that pre-existing PI resistance mutations may have an impact on the development of bevirimat resistance.

In the new study, wild-type HIV, as well as HIV bearing major mutations conferring PI resistance, were grown in cell culture in the presence of bevirimat at suboptimal concentrations. Bevirimat resistance developed after several weeks in both wild-type and PI-resistant HIV, but took more than twice as long to develop in the PI-resistant virus. The bevirimat resistance mutation that appeared in PI-resistant virus was located at th
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
(Date:1/23/2015)... FORT MYERS, Fla. , Jan. 23, 2015  Today ... approval of Novartis, Bexsero® for the prevention of ... to 25. Bexsero and Pfizer,s vaccine Trumenba®, which received ... in helping prevent this devastating disease. ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease ... health care leaders and a new study analyzing the impact ... PFCD is a nationwide coalition working to educate policy makers and ... at the Capitol was focused on how the Iowa ...
(Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... authorization for prescription medications is a time-consuming process for ... faxes and hard-copy request forms. While some on-line solutions ... solution and one that is integrated with available e-prescribing ... in the marketplace, CVS Caremark (NYSE: CVS ...
... SHENZHEN, China, May 16, 2011 /PRNewswire-Asia/ -- Global ... or the "Company"), a China-based leading vertically integrated ... and herbal cultivation businesses through its subsidiaries in ... its unaudited financial results for the first quarter ...
Cached Medicine Technology:CVS Caremark to Pilot Electronic Prior Authorization to Help Speed Patient Access to Prescription Medication 2CVS Caremark to Pilot Electronic Prior Authorization to Help Speed Patient Access to Prescription Medication 3Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 2Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 3Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 4Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 5Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 6Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 7Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 8Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 9Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 10Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 11
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz Chiropractic ... treated just about every type of injury that can result from ... same twenty-plus years, the team at Doctors on Liens ... possible doctor. With the combined breadth of experience between ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... January 22, 2015 Compare-autoinsurance.org has released a new ... by an auto insurance policy . , Some types ... Clients should check the newly released blog post to see if ... and dangerously damaged vehicles are some of the cars that cannot ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... new study researchers say they found that chest pain ... elderly patients treated // with angioplasty and those on ... these benefits earlier. ,Patients treated with surgery ... treated patients required more antianginal drugs throughout the study. ...
... most common symptom in patients with plaque build-up in ... medication // nifedipine (Adalat or Procardia) may be safe ... angina symptoms and prolongs heart-problem-and-procedure-free survival. ,For ... nifedipine gastrointestinal therapeutic system or a placebo. GITS modifies ...
... solvents and cleaning products at home may increase the ... findings from a recent study. Researchers found the levels ... the homes of children with asthma. Volatile organic compounds ... polishes, room fresheners, fitted carpets, and cigarette smoke. ...
... Researchers from the University of Florida College of Medicine ... for hypertension // in older patients. Researchers say most ... blood pressure, so this study was set up to ... study found patients had similar outcomes when they took ...
... frustrated when patients ask them what type of bed is ... done// on this issue to support their answers. Therefore, researchers ... a firm vs. a medium-firm mattress when it comes to ... had their own bed mattresses replaced with either a firm ...
... degenerative joint disease and one of the oldest and ... joint’s cartilage breaks down and the bones rub against ... ,An international, multi-center study shows an effective treatment for ... Prexige. The drug was found to reduces gastric complications ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: